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Virus infection of mammalian cells is sensed by pattern recognition receptors and leads to an
innate immune response that restricts virus replication and induces adaptive immunity. In
response, viruses have evolved many countermeasures that enable them to replicate and be
transmitted to new hosts, despite the host innate immune response. Poxviruses, such as vaccinia
virus (VACV), have large DNA genomes and encode many proteins that are dedicated to host
immune evasion. Some of these proteins are secreted from the infected cell, where they bind and
neutralize complement factors, interferons, cytokines and chemokines. Other VACV proteins
function inside cells to inhibit apoptosis or signalling pathways that lead to the production of
interferons and pro-inflammatory cytokines and chemokines. In this review, these VACV
immunomodulatory proteins are described and the potential to create more immunogenic VACV
strains by manipulation of the gene encoding these proteins is discussed.
Introduction
Vaccinia virus (VACV) is the live vaccine used to
immunize against smallpox (Fenner et al., 1988) and,
whilst it remains the only vaccine to have eradicated a
human disease, its origin and natural host are unknown
(Baxby, 1981). VACV is the most intensively studied
member of the genus Orthopoxvirus of the family
Poxviridae (Moss, 2007). It is distinct from cowpox virus
(CPXV), the virus presumed to have been used by Edward
Jenner in 1796 when he introduced vaccination against
smallpox. Properties of orthopoxviruses include a dsDNA
genome of approximately 200 kb, a cytoplasmic replication
cycle, the production of two distinct forms of infectious
virus particle called intracellular mature virus (IMV) and
extracellular enveloped virus (EEV), virus-encoded
enzymes for transcription and DNA replication, and many
virulence factors that modulate the innate immune
response to infection.
Although smallpox was declared eradicated in 1980,
interest in VACV has continued because of the devel-
opment of VACV as a vector for the expression of foreign
genes, and because VACV represents an excellent model for
studying virus–host interactions. In the early 1980s,
recombinant VACV strains expressing foreign genes were
constructed (Mackett et al., 1982; Panicali & Paoletti, 1982)
and shown to have potential application as new live
vaccines (Panicali et al., 1983; Smith et al., 1983a, b;
Paoletti et al., 1984) that could induce both antibody and
T-cell responses to the foreign antigen (Bennink et al.,
1984). The capacity of VACV for foreign DNA is at least
25 kb (Smith & Moss, 1983) and therefore multiple foreign
genes can be expressed simultaneously to create a
polyvalent vaccine (Perkus et al., 1985). Apart from the
use of recombinant VACVs as live vaccines, these viruses
are valuable research tools that have been used, for
instance, to identify which virus antigens are recognized
by CTLs (Yewdell et al., 1985; Bennink et al., 1986, 1987;
McMichael et al., 1986; Osman et al., 1999) and to identify
the human immunodeficiency virus (HIV) co-receptor
fusin (CXCR4) (Feng et al., 1996). Whilst the concept of
reusing VACV as a vaccine for other infectious diseases was
attractive, the imperfect safety record associated with its
use (Lane et al., 1969) necessitated improvements in safety
before its reuse in man. To this end, researchers sought to
identify VACV virulence genes and then remove these from
the genome to create stably attenuated vaccines. This
search and other approaches led to the discovery of the
many VACV proteins that inhibit the innate response to
infection, the subject of this review. For earlier reviews of
this topic, see Smith (1994), Smith et al. (1997b), Moss &
Shisler (2001), Alcamı´ (2003) and Seet et al. (2003).
The linear dsDNA genome of VACV and other orthopox-
viruses may be divided into a conserved central region of
about 100 kb that encodes proteins that are mostly
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essential for virus replication, and more variable terminal
regions, which encode non-essential factors affecting
virulence, host range and immunomodulation and repre-
sent about half the virus genes (Gubser et al., 2004). The
proteins encoded by these terminal genes have diverse
functions, but many target the innate immune system and
can be grouped according to which component they target.
The function of some of these proteins was inferred from
amino acid similarity with cellular proteins of known
function. For instance, the VACV complement protein
(VCP) (Kotwal & Moss, 1988), the soluble IL-1 receptor
(Smith & Chan, 1991; Alcamı´ & Smith, 1992) and the 3b-
hydroxysteroid dehydrogenase (3b-HSD) enzyme (Moore
& Smith, 1992). In other cases, however, the protein
function was deduced by experimentation or determina-
tion of its three-dimensional structure, comparison with
protein structure databases and experimentation. The
study of these proteins has established some general
principles. First, these immunomodulatory proteins are
very numerous and VACV devotes between one-third and
one-half of its genetic coding capacity to them. Secondly,
VACV has many gene families that indicate duplication
and diversification of an ancestral gene (Goebel et al., 1990;
Smith et al., 1991). Thirdly, the great majority of these
proteins are expressed early during infection to combat
the innate immune system rapidly, although a notable
exception is the soluble IL-1 receptor (IL-1R), which is
expressed late during infection (Alcamı´ & Smith, 1992).
Fourthly, there are several examples where multiple
proteins apparently target the same cellular pathway and
yet loss of each protein individually alters the virus
phenotype in vivo, indicating that the proteins have non-
redundant functions. Lastly, a protein may have multiple
immunomodulatory functions.
This review focuses largely on proteins from VACV rather
than poxviruses in general and this is dictated by length
restrictions. Thus, we regret it has not been possible to cite
all articles on this topic; however, many of the principles
learnt by VACV are applicable to these other viruses, and in
some cases reference is made to other orthopoxviruses.
Different aspects of the innate immune system, and how
VACV interferes with these, are described in turn, and the
review concludes with a consideration of the influence of
virus immunomodulators on virus virulence and immu-
nogenicity, and future prospects for development of
therapeutics and vaccines.
Complement
The complement system represents an important host
defence that can destroy viruses or virus-infected cells and
promote the phagocytosis of virions that have been
opsonized by antibody via recognition of the Fc region of
bound immunoglobulin. To counteract complement,
VACV expresses an abundant, 35 kDa protein called VCP
that is secreted from infected cells and contains four short
consensus repeats that are characteristic of the family of
complement control proteins (Kotwal & Moss, 1988). VCP
binds to complement components C3b and C4b and
functions as a co-factor with factor I in promoting cleavage
of C3b and C4b and thereby blocks activation of the
complement cascade by either the classical or alternative
pathway (McKenzie et al., 1992). VCP contributes to virus
virulence because a VACV strain engineered to lack the
VCP gene is attenuated in vivo (Isaacs et al., 1992a). More
recently, it was reported that VCP binds to the A56 protein
(also called the haemagglutinin), which is present on the
surface of infected cells and EEV particles (DeHaven et al.,
2010). This interaction helps defend cells and EEV particles
against complement. A second VACV protein, B5, is also a
member of the complement protein family and has four
short consensus repeats (Takahashi-Nishimaki et al., 1991).
B5 is a type I integral membrane glycoprotein and is
present in the EEV outer envelope (Engelstad et al., 1992;
Isaacs et al., 1992b), but no role in protection against
complement has been described. Instead, B5 is needed for
the formation of EEV and thereby promotes virus
dissemination (Engelstad & Smith, 1993; Wolffe et al.,
1993; reviewed by Smith et al., 2002; Roberts & Smith,
2008). VACV has another defence against complement that
is mediated by acquisition of host complement control
proteins CD46, CD55 and CD59 in the EEV envelope
(Vanderplasschen et al., 1998). The presence of CD55, in
particular, helps the EEV particle escape destruction by
complement and explains the greater resistance of EEV to
complement compared with IMV particles, which lack
these host complement proteins and are very sensitive to
destruction by complement.
These virus defences against complement are beneficial but
not absolute. For instance, it is known that, whilst the EEV
particle is more resistant to complement than IMV in the
absence of specific antibody (Vanderplasschen et al., 1998),
the EEV particle can be neutralized by antibody directed
against the A33 protein if complement is present (Lustig
et al., 2004), and neutralization via antibodies to B5 is
enhanced by, or dependent on, complement (Benhnia et al.,
2009). Furthermore, the protective efficacy of antibody to
EEV is mediated by complement and Fc receptors (Cohen
et al., 2011).
Interferons
Interferons (IFNs) are species-specific, secreted glycopro-
teins with potent antiviral effects. They were discovered in
1957 (Isaacs & Lindenmann, 1957; Isaacs et al., 1957) and
are grouped into three classes. Type I IFNs include IFN-a
and IFN-b, and others such as IFN-k, IFN-d and IFN-v,
and all exert their effects via the type I IFN receptor, which
is expressed ubiquitously. Type II IFN (IFN-c) is secreted
by activated immune cells [principally natural killer (NK)
and T-cells], and activates macrophages and promotes
a cell-mediated [T-helper 1 (Th1)] adaptive immune
response. Type III IFNs (IFN-ls) are also secreted in
response to virus infection, but the type III IFN receptor
G. L. Smith and others
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has a more limited tissue distribution. Type I, II and III
IFNs each play important roles in anti-VACV defence, as
illustrated by the different in vivo responses to infection
when these IFNs, or their receptors (IFNRs), are either
absent from the host or expressed by the virus (Kohonen-
Corish et al., 1990; van den Broek et al., 1995; Bartlett et al.,
2005).
The IFN response is initiated upon sensing of viral
pathogen-associated molecular patterns (PAMPs) by
host cell pattern recognition receptors (PRRs) (Fig. 1).
These include membrane-associated Toll-like receptors
(TLRs), retinoic acid inducible gene I (RIG-I)-like
receptors (RLRs), such as RIG-I and melanoma differenti-
ation antigen 5 (MDA5) that detect foreign cytoplasmic
RNA, and putative cytosolic dsDNA sensors, such as absent
in melanoma 2 (AIM2), RNA polymerase III, DNA-
dependent activator of IFN-regulatory factors (DAI),
IFN-inducible factor 16 (IFI16), DNA protein kinase
(DNA-PK) and cyclic GMP-AMP synthase (cGAS)
(reviewed by Paludan & Bowie, 2013). Engagement of
PRRs induces signalling cascades that culminate in the
activation of transcription factors, such as IFN-regulatory
factors (IRF) 3 and IRF7, NF-kB and activator protein 1
(AP-1), their translocation into the nucleus and transcrip-
tion of genes encoding type I IFNs (notably IFN-b),
cytokines and chemokines. IRF3, NF-kB and AP-1 together
form a complex called the enhanceosome that binds to the
IFN-b promoter and stimulates transcription (Wathelet
et al., 1998). IRF7 induces the transcription of IFN-a genes
as well as the IFN-b gene (Marie et al., 1998), and is
responsible for the high levels of IFN-as secreted by
specialized plasmacytoid dendritic cells (Kato et al., 2005).
IFNs are secreted from the cell and then engage their
cognate receptor on the same cell (autocrine signalling) or
neighbouring cells (paracrine signalling), and thereby
initiate the Janus kinase (JAK)/signal transducer and
activator of transcription (STAT) signalling cascades. Type
I and III IFNs activate signalling pathways that lead to the
formation of a complex called IFN-stimulated gene factor 3
(ISGF3) (comprising STAT1, STAT2 and IRF9) (Fig. 1).
ISGF3 activates transcription of IFN-stimulated genes
(ISGs) by binding to IFN-stimulated response elements
(ISREs) present in the promoters of these genes. Type II IFN
(IFN-c) signals via STAT1 homodimers that activate
transcription by binding to c-activated sequences (GAS) in
a subset of ISG promoters. For a review of JAK/STAT
signalling, see Stark & Darnell (20120. Thus, IFN induces the
co-ordinated expression of several hundred ISGs [including
protein kinase R (PKR), 29-59-oligoadenylate synthase
(OAS), ISG15 and Mx proteins] that together confer an
antiviral state. PKR is activated by dsRNA and then
phosphorylates the eukaryotic translation initiation factor
(eIF)2a, thereby causing inhibition of protein synthesis.
OAS synthesizes 29-59-oligoadenylates upon its activation by
dsRNA, and these activate RNase L, which degrades viral
and cellular mRNAs (Silverman, 2007). The ubiquitin-like
protein ISG15 becomes conjugated to a range of proteins,
including IRF3, RIG-I, human MxA and PKR, and stabilizes
these targets against degradation (Zhao et al., 2005; Lu et al.,
2006; Kim et al., 2008), thus modulating the IFN-stimulated
antiviral response. ISG15 may also be secreted from cells
and contribute to defence against microbial infection
(Bogunovic et al., 2012). For a review of IFNs, their anti-
viral activity and virus evasion strategies see Randall &
Goodbourn (2008).
Early studies indicated that VACV was able to interfere
with IFNs or their mechanism(s) of action. Forty years
ago, it was noted that vesicular stomatitis virus (VSV)
replication was inhibited by prior treatment of susceptible
cells with IFN. However, if the cells were treated with IFN
and then co-infected with VSV and VACV, VSV replication
was restored (Thacore & Youngner, 1973). This implied
that VACV was providing some factor(s) in trans that
overcame the IFN-mediated blockade of VSV replication.
Later, it was demonstrated that this factor prevented PKR
and OAS activation (Whitaker-Dowling & Youngner, 1983;
Paez & Esteban, 1984), bound dsRNA and was encoded by
the E3L gene (Chang et al., 1992). Other early studies
revealed that VACV mutants with large deletions in the
terminal regions of the virus genome had increased
sensitivity to IFN, and that the presence of IFN would
prevent formation of such deletion mutant viruses (Paez &
Esteban, 1985), suggesting that these regions encode
proteins that antagonize the antiviral action of IFNs.
It is now known that viruses inhibit the IFN response at
multiple levels, and many of these are illustrated by VACV
(Fig. 1). First, VACV restricts IFN production by mini-
mizing the production or recognition of PAMPs, express-
ing proteins that block the PRR-induced signalling path-
ways that activate transcription factors leading to IFN
induction, and by inhibiting host protein synthesis.
Secondly, VACV secretes proteins from the infected cell
to capture IFNs in solution or on the cell surface, and
prevent engagement of IFN receptors by IFNs. Thirdly,
VACV blocks signal transduction induced by IFNs binding
to their receptors. Finally, additional VACV proteins act
within the infected cell to inhibit the antiviral action of
IFN-induced proteins. Individual VACV proteins can
possess multiple anti-IFN activities, as exemplified by
the E3 protein, which inhibits B-DNA-stimulated IFN-b
transcription in mouse embryonic fibroblasts (Wang et al.,
2008), sensing of RNAs produced by DNA-dependent RNA
polymerase transcription of AT-rich DNA (Marq et al.,
2009; Valentine & Smith, 2010) and the antiviral action of
ISG15 in mouse embryonic fibroblasts (Guerra et al.,
2008).
Blocking induction of IFNs
The simplest way of avoiding the antiviral activity of IFNs
is to prevent their production, and VACV utilizes several
mechanisms to accomplish this. The first is to minimize the
production of dsRNA, an important PAMP leading to IFN
production. To do this, the VACV genome is arranged with
Vaccinia virus immune evasion
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genes located at the left or right terminal region of the
genome being transcribed predominantly outward towards
the genomic terminus. With transcription from only one
DNA strand in these regions, dsRNA formation is prevented.
In the central region of the genome, although genes are
transcribed equally from both strands, genes are generally
arranged in blocks with leftward and rightward transcribed
blocks of genes alternating. Where there is convergent
transcription, especially early during infection, there are
multiple intergenic transcriptional termination sequences to
prevent the formation of overlapping transcripts and so
diminish dsRNA formation (Smith et al., 1998).
A second strategy is to inhibit host protein synthesis, so
that production of host IFNs and other pro-inflammatory
molecules is diminished shortly after infection. VACV
inhibits host protein synthesis within a few hours of
infection (Moss & Salzman, 1968). A contributory factor is
the increased degradation of host mRNAs (Rice & Roberts,
1983) mediated by the D9 and D10 proteins, which
recognize mRNAs and cleave off their 59 methylated caps
(Parrish & Moss, 2006, 2007; Parrish et al., 2007). These
proteins also cause turnover of VACV mRNAs, thereby
promoting a switch from early to intermediate and late
protein synthesis. Although most host mRNAs are down-
regulated during infection (Brum et al., 2003; Guerra et al.,
2004), VACV can preserve or increase some cellular
functions by activating host gene expression, for instance,
genes controlled by the transcription factor hypoxia-
inducing factor (HIF)-1a. Early after infection, VACV
strain Western Reserve (WR) protein C16 binds and
inhibits prolyl hydroxylase domain-containing protein 2
(PHD2) (Mazzon et al., 2013). PHD2 is an oxygen sensor
and under normoxic conditions can hydroxylate and
induce proteosomal degradation of HIF-1a. However,
once PHD2 is inhibited by C16, HIF-1a remains stable
and moves into the nucleus to activate genes containing a
HIF-responsive element, so mimicking a hypoxic response
under normoxic conditions (Mazzon et al., 2013).
A third strategy is to prevent binding of PAMPs by PRRs.
The VACV E3 protein sequesters dsRNA via a C-terminal
dsRNA-binding domain and thereby prevents activation of
dsRNA-binding PRRs (Chang et al., 1992). E3 also blocks
the production of IFN following sensing of AT-rich dsDNA
by RNA polymerase III, because this leads to RNA
formation, which is bound by E3 (Marq et al., 2009;
Valentine & Smith, 2010). E3 has an N-terminal Z-DNA-
binding domain of unknown function, and both this and
the C-terminal RNA-binding domain contribute to
virulence (Brandt & Jacobs, 2001; Kim et al., 2003).
VACV also encodes a protein to block the recognition of
Fig. 1. IFN signalling and its antagonism by VACV. A virus infection is sensed by PRRs within the cytosol or in endosomes, and
these trigger signalling cascades leading to activation of transcription factors NF-kB, IRF3 and AP-1. These enter the nucleus
and stimulate transcription of the IFN-b gene. IFN-b is then secreted from the cell and binds to the type I IFNR on the same or
adjacent cells. This triggers activation of the JAK/STAT pathway leading to assembly of the ISGF3 complex in the nucleus and
the transcription of hundreds of ISGs. The expression of these proteins, such as Mx, PKR and OAS, in the cytoplasm renders
the cell more resistant to subsequent virus infection. The positions at which viral proteins can inhibit the production or action of
IFN are shown by red stars, and many of these are illustrated by VACV proteins. This figure is adapted from an excellent review
on IFNs and their antiviral activities by Haller et al. (2006). See main text for abbreviations.
G. L. Smith and others
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cytosolic DNA by DNA-PK, which was shown recently to
be a PRR for IRF3-dependent innate immunity (Ferguson
et al., 2012). The C-terminal region of VACV strain WR
protein C16 binds the Ku complex (part of DNA-PK) and
thereby blocks the recruitment of DNA-PK to DNA and
inhibits the induction of IRF3-dependent chemokines,
cytokines and IFN (Peters et al., 2013).
A fourth strategy is to express proteins that act downstream
of PRR binding to PAMPs to block the intracellular
signalling pathways leading to IRF3 or NF-kB activation
that are required for IFN induction (see Figs 2 and 3,
discussed below). There are many such proteins and they
are grouped according to the pathway they target.
Inhibitors of NF-kB activation
VACV intracellular proteins that inhibit NF-kB activation
are numerous and include A46, A49, A52, B14, C4, E3, K1,
K7, M2 and N1. These proteins are all expressed early
during infection but inhibit NF-kB activation at differing
stages in the signalling pathway (Fig. 2). Protein A46 binds
to several Toll/IL-1R (TIR) domain-containing adaptor
molecules [myeloid differentiation primary response gene
88 (MyD88), Myd88 adaptor-like (MAL), TIR-domain-
containing adaptor-inducing interferon-b (TRIF) and
TRIF-related adaptor molecule (TRAM)] that associate
with the cytoplasmic tails of TLRs (Bowie et al., 2000; Stack
et al., 2005). Binding to these multiple ligands enables A46
Fig. 2. NF-kB signalling pathway and its antagonism by VACV. The pathway leading to activation of NF-kB can be activated by
external or internal signals. The pathway illustrated here is activated by TNF binding to the TNFR, IL-1 binding to the IL-1R or
TLR ligands binding to TLRs. Engagement of these receptors by their ligands leads to signalling cascades that converge on the
IKK complex and results in phosphorylation of IKKa or IKKb on serine residues in their activation loops. Once IKKb (in particular)
is activated, it phosphorylates the inhibitor of kB (IkBa) leading to its recognition by the E3 ubiquitin ligase b-TrCP, and its
ubiquitination and degradation by the proteasome. This releases the NF-kB subunits, which then translocate into the nucleus
and induce transcription from NF-kB-responsive genes, such as those encoding cytokines, chemokines and IFNs. The sites of
action of VACV proteins B15, CrmC, CrmE, E3, A46, A52, K7, B14, N1, C4, A49, K1 and M2 that inhibit the NF-kB pathway
are shown and are described further in the text.
Vaccinia virus immune evasion
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to inhibit activation of mitogen-activated protein (MAP)
kinases, NF-kB and IRF3 and, therefore, the induction of
IFN-b. Interactions with TRIF and TRAM also enable A46
to block TLR3/4-mediated activation of IRF3 (Fig. 3). The
A52 protein also acts early in the activation pathway and
inhibits IL-1 and TLR-induced activation of NF-kB by
binding to IL-1R-associated kinase 2 (IRAK2) and tumour
necrosis factor (TNF) receptor-associated factor 6 (TRAF6)
(Bowie et al., 2000; Harte et al., 2003). The structure of
protein A52 has been solved and revealed a B-cell
lymphoma-2 (Bcl-2) fold (Graham et al., 2008) that is
conserved in several other VACV proteins that function as
inhibitors of innate immune signalling pathways (see
below). Protein K7 is also a member of the Bcl-2 family
(Kalverda et al., 2009) and binds to IRAK2 and TRAF6 and
suppresses TLR-dependent NF-kB activation (Schro¨der
et al., 2008; Oda et al., 2009). K7 also binds the DEAD-box
RNA helicase 3 (DDX3) and inhibits PRR-induced IFN-b
induction by preventing IRF3 activation (Schro¨der et al.,
2008). These three proteins (A46, A52 and K7) inhibit
TLR- and IL-1b-mediated NF-kB activation, but not NF-
kB activation mediated by TNF (Fig. 2). In contrast, all the
other VACV proteins targeting NF-kB activation act at, or
downstream of, the convergence of IL-1- and TNF-
mediated signalling and so inhibit both pathways.
Protein N1 inhibits NF-kB activation (DiPerna et al.,
2004), but the report that it binds to the inhibitor of kB
Fig. 3. IRF3 signalling pathway and its antagonism by VACV. RNA sensing by RIG-I or MDA5, and DNA sensing by RNA
polymerase III induces signalling via the mitochondrial-associated adaptor MAVS (also known as IPS-1, CARDIF and VISA).
Signalling from other cytoplasmic DNA sensors such as DNA-PK and IFI16 involves the adaptor protein STING. Signalling from
TLR3 (that is endosomal) and TLR4 (found at the plasma membrane and in endosomes) requires the adaptor TRIF, whilst TRAM
acts as a bridging adaptor between TRIF and TLR4. The IRF3 kinases, TBK1 and IKKe, are activated subsequent to activation of
TRAF3, and form complexes with the proteins NAP1, SINTBAD, TANK and DDX3. Upon phosphorylation, IRF3 undergoes
dimerization and nuclear translocation. Within the nucleus, activated IRF3 binds to IRF3-binding sites within the promoters of
IFN-b and other IRF3-dependent genes. The sites of action of VACV proteins E3, C16, A46, K7, C6 and N2, which inhibit the
IRF3 pathway, are shown and are described further in the text.
G. L. Smith and others
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kinase (IKK) complex has been disputed (Chen et al., 2008)
and its mechanism of action remains uncertain. N1 is
dimeric (Bartlett et al., 2002) and has a Bcl-2 fold (Aoyagi
et al., 2007; Cooray et al., 2007), and mutagenesis of the N1
dimer surface inhibits both dimerization and the ability to
block NF-kB activation, suggesting that either N1 acts as a
dimer or it uses the dimer interface to block NF-kB
(Maluquer de Motes et al., 2011).
Protein B14 binds to IKKb and prevents its phosphoryla-
tion and activation by upstream kinases, thereby blocking
IKKb-mediated phosphorylation of the inhibitor of kB
(IkBa) (Chen et al., 2008). The structure of B14 also
revealed a Bcl-2 fold (Graham et al., 2008), and targeted
mutation of an exposed hydrophobic surface eliminated
binding of IKKb and inhibition of NF-kB activation
(Benfield et al., 2011). Protein C4 inhibits activation of
NF-kB at, or downstream of, the IKK complex by an
unknown mechanism (Ember et al., 2012). Protein E3
inhibits NF-kB activation in both PKR-dependent and
-independent manners (Myskiw et al., 2009) and also by
antagonizing the RNA polymerase III–dsDNA sensing
pathway (Marq et al., 2009; Valentine & Smith, 2010).
Recently, protein A49 was shown to stabilize phosphory-
lated IkBa by molecular mimicry (Mansur et al., 2013).
Near the N terminus of A49, there is a short sequence
containing conserved serine residues that are present in
IkBa and that, in IkBa, are phosphorylated by IKKb.
Normally, once IkBa is phosphorylated by IKKb, p-IkBa is
recognized and ubiquitinated by the E3 ubiquitin ligase b-
transducing repeat-containing protein (b-TrCP) leading to
p-IkBa degradation by the proteasome. A49 functions by
binding to b-TrCP so that, even if IkBa is phosphorylated,
it is not recognized and ubiquitinated by b-TrCP, and p-
IkBa remains bound to NF-kB in the cytoplasm (Mansur
et al., 2013). Protein K1 was also reported to inhibit NF-kB
signalling in rabbit kidney epithelial cells by preventing the
degradation of IkBa, but the mechanism remains unclear
(Shisler & Jin, 2004). Finally, protein M2 reduces
extracellular signal-regulated kinase 2 (ERK2) phosphor-
ylation induced by phorbol myristate acetate and prevents
p65 nuclear translocation (Gedey et al., 2006).
Despite inhibiting the NF-kB activation pathway at
multiple places, these VACV proteins are non-redundant,
because loss of any individual protein gives an in vivo
phenotype (see below).
Inhibitors of IRF3 activation
The kinases TANK-binding kinase 1 (TBK1) and IKKe lie at
the convergence of several pathways leading to IRF3
activation (Fig. 3), and thus provide an attractive target
for viral antagonism of IFN production. For example, the
VACV C6 protein interacts with the scaffold adaptor
proteins for these kinases, NAK-associated protein 1
(NAP1), TRAF family member-associated NF-kB activator
(TANK) and similar to NAP1 TBK1 adaptor (SINTBAD),
and prevents TBK1/IKKe-dependent activation of IRF3 and
IRF7 (Unterholzner et al., 2011). A related VACV protein,
K7, binds to DDX3, and led to the discovery that DDX3 is an
adaptor of TBK1/IKKe and can also directly bind the IFN-b
promoter (Schro¨der et al., 2008; Soulat et al., 2008; Oda
et al., 2009). Thus, K7 antagonizes both TLR-dependent and
-independent IFN-b activation. As noted earlier, protein
C16 inhibits IRF3 activation by disrupting recognition of
dsDNA by DNA-PK (Peters et al., 2013). In addition, as
mentioned above, protein A46 binds to TRIF, TRAM, MAL
and Myd88 and so can also block IRF3 activation (Stack
et al., 2005). Lastly, protein N2 inhibits IRF3 activation
downstream of IRF3 phosphorylation and nuclear trans-
location via an unknown mechanism (Ferguson et al., 2013).
Collectively, this wide array of proteins that block IRF3 and
NF-kB activation provides a profound block on IFN-b
production from VACV-infected cells.
Blocking IFN reaching its receptors
The strategies outlined above are effective means by which
VACV can restrict the production of IFN from infected
cells. To combat IFNs produced from uninfected cells,
VACV has another strategy, namely the release of decoy
IFN receptors from the infected cells (Fig. 4).
VACV strain WR protein B18 is a type I IFN-binding
protein and acts both in solution and when associated with
the cell surface via glycosaminoglycans (GAGs) to sequester
type I IFNs (Colamonici et al., 1995; Symons et al., 1995;
Alcamı´ et al., 2000; Montanuy et al., 2011). B18 binds type
I IFNs from a broad range of species (Symons et al., 1995);
however, it only inhibits IFN-a efficiently and defence
against IFN-b relies more on intracellular proteins
(Waibler et al., 2009). This strategy is logical because
IFN-a (leukocyte IFN) is produced largely, and in high
levels, by activated dendritic cells that are recruited to sites
of inflammation and so require neutralization outside the
cell by a decoy receptor. In contrast, IFN-b (fibroblast IFN)
is also produced by fibroblasts and epithelial cells before
leukocytes are recruited to the site of infection and so can
be targeted by inhibition of signalling pathways leading to
IFN-b promoter activation. The ability of B18 to bind to
the surface of cells enables it to prevent the IFN-mediated
antiviral state in uninfected cells, which therefore remain
susceptible to virus replication as it spreads.
Type II IFN is also neutralized via a VACV soluble decoy
IFN receptor, protein B8, which binds IFN-c outside cells
and, unlike the cellular IFN-cR, can also dimerize in the
absence of IFN-c (Alcamı´ & Smith, 2002). The B8 protein
shares amino acid similarity to the cellular IFN-cR but
lacks the transmembrane and cytoplasmic domains found
in the cellular IFN-cR (Upton et al., 1992; Alcamı´ & Smith,
1995; Mossman et al., 1995), and this enabled its function
to be predicted. A structural study of the closely related
IFN-c-binding protein from ectromelia virus (ECTV, the
causative agent of mousepox) showed that the complex of
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the ECTV IFN-c-binding protein and IFN-c consisted of
four molecules of the ECTV protein in complex with two
IFN-c dimers, and that tetramerization of the ECTV IFN-c-
binding protein is mediated by a C-terminal helix–turn–
helix domain (Nuara et al., 2008).
The study of these decoy IFN receptors provided an
opportunity to investigate the unknown origin of VACV
because of the species-specific nature of IFNs and their
receptors. It seemed logical that VACV would have evolved
proteins to bind and neutralize IFNs from its natural host
species, and therefore studying the binding of B18 and B8 to
type I or type II IFNs from different species might indicate a
natural host for VACV. However, both B18 and B8 bound
type I or type II IFNs from many different species, although
they bound less well to murine IFNs (Alcamı´ & Smith, 1995;
Mossman et al., 1995; Symons et al., 1995). This broad IFN
specificity did not reveal a likely host for VACV but did
indicate that these proteins would be useful to help VACV
combat IFNs in many hosts and thereby help facilitate a
broad host range (Alcamı´ & Smith, 1996b). It has been
established that both B18 (Symons et al., 1995) and B8
(Symons et al., 2002b) contribute to VACV virulence where
the host IFN is bound by the virus protein. Interestingly, the
yatapoxvirus, Yaba-like disease virus, encodes protein Y136,
which is related to VACV WR B18 but can inhibit both type
I and type III IFNs (Huang et al., 2007).
Inhibiting IFN-induced signal transduction
Another mechanism to block the action of IFNs is to
inhibit signal transduction induced by IFN binding to IFN
Fig. 4. IFN-induced signalling pathways and their inhibition by VACV. Type I, II and III IFNs bind to their receptors on cells and
induce signalling via the JAK/STAT pathways. Binding of type I or type III IFN causes activation of the JAK1/TYK2 kinases, and
these then recruit and phosphorylate STAT1 and STAT2. Once phosphorylated, STAT1 and STAT2 form a heterodimer that
associates with IRF9 forming ISGF3, which activates transcription of hundreds of ISGs with an ISRE. Type II IFN-stimulated
phosphorylation of JAK1/JAK2 causes phosphorylation of STAT1. STAT1 homodimers (GAF complex) translocate into the
nucleus and bind to GAS elements. VACV inhibits the actions of IFNs both intracellularly and extracellularly. The mechanisms of
action of VACV extracellular proteins B8 and B18 and intracellular protein VH1 are illustrated and described in the text.
G. L. Smith and others
2374 Journal of General Virology 94
Downloaded from www.microbiologyresearch.org by
IP:  195.195.217.51
On: Thu, 22 Sep 2016 14:02:54
receptors. Signalling events within the JAK/STAT pathway
that are elicited in response to the binding of type I, II or
III IFNs are shown in Fig. 4.
The VACV protein VH1 is a virion-associated phosphatase
that is brought into infected cells with the infecting virion
and rapidly dephosphorylates STAT1 and STAT2, thereby
inhibiting signalling from all IFN receptors (Najarro et al.,
2001; Mann et al., 2008). Given the redundancy in
inhibitors of the IRF3 and NF-kB activation pathways, it
is quite possible that other VACV inhibitors of the JAK/
STAT signalling pathway exist.
Inhibiting IFN-induced antiviral proteins
Finally, VACV also encodes proteins that counter the
effects of proteins encoded by ISGs. The E3 dsRNA-
binding protein sequesters dsRNA to prevent activation of
PKR, OAS and other dsRNA sensors. E3 also binds ISG15
and prevents its antiviral action (Guerra et al., 2008).
Another example is VACV protein K3, which has amino
acid similarity to eIF2a, and acts as a non-phosphorylatable
pseudo-substrate for PKR and thus competitively inhibits
the phosphorylation of eIF2a by PKR (Beattie et al., 1991;
Carroll et al., 1993). Lastly, the ability of the host-range
genes C7 and K1 to support VACV replication in
permissive cell lines is thought to be due to antagonism
of currently undefined IFN-induced antiviral factor(s)
(Meng et al., 2009).
Cytokines
Pro-inflammatory cytokines such as TNF, IL-1 and IL-18
amplify the innate immune response to virus infection and
shape the adaptive immune response to follow. TNF also
has direct antiviral activity by the induction of apoptosis of
infected cells (see below). VACV has evolved strategies to
block these cytokines at multiple levels in a manner
analogous to the inhibition of IFN. These include the
inhibition of proteolytic maturation of specific cytokines,
expression of soluble decoy receptors and inhibition of
cytokine-induced signal transduction. These principles are
illustrated with proteins targeting IL-1, IL-18 and TNF.
Targeting IL-1
IL-1 is a pro-inflammatory cytokine that activates NF-kB
and leads to induction of inflammatory mediators such as
cyclo-oxygenase-2 (COX-2) and inducible nitric oxide
synthase (iNOS). It exists in three forms, IL-1a and IL-1b,
which can both activate IL-1R-mediated signalling, and the
IL-1R antagonist protein, which binds to the IL-1R without
signalling (reviewed by Dinarello, 2006). The production
and secretion of IL-1b usually requires two signals; a first
signal, often NF-kB activity, induces the transcription and
synthesis of an inactive intracellular form, pro-IL-1b.
VACV can therefore inhibit the synthesis of pro-IL-1b by
inhibiting NF-kB (see above). The second signal is required
to activate caspase-1; this can cleave pro-IL-1b to form IL-
1b, which is then secreted from the cell. In response to
virus infection, this second signal is provided by the
activation of inflammasomes, large protein complexes
containing PRRs, which activate caspase-1. Various
inflammasomes, which are activated by different molecular
stimuli, can detect VACV infection and contribute to IL-1b
production (Hornung et al., 2009; Gerlic et al., 2013), and
VACV has evolved mechanisms to inhibit this process. The
F1 protein can bind directly to the nucleotide-binding
domain, leucine-rich repeat and pyrin domain containing
protein 1 (NLRP1) inflammasome and reduce the amount
of active caspase-1 and IL-1b secretion (Gerlic et al., 2013).
In addition, to prevent pro-IL-1b cleavage within infected
cells, the VACV strain WR protein B13 [also called serine
proteinase inhibitor 2 (SPI-2) and cytokine response
modifier A (CrmA) in CPXV] binds caspase-1 and blocks
pro-IL-1b cleavage (Ray et al., 1992; Dobbelstein & Shenk,
1996; Kettle et al., 1997). This has the additional function
of preventing caspase-1-induced cell death. Not all VACV
strains have a functional B13R gene, and in several strains,
including Copenhagen and Lister, the B13 protein is not
produced (Kettle et al., 1995).
The strategy of preventing IL-1b formation is restricted to
infected cells, and so uninfected cells recruited to infected
tissue can produce IL-1b freely. To combat IL-1b from this
source and any IL-1b that escapes blocking strategies from
infected cells, VACV strain WR expresses a soluble IL-1R
that is released from infected cells to capture IL-1b in
solution (Alcamı´ & Smith, 1992; Spriggs et al., 1992).
Protein B15 shows amino acid similarity to the extracellular
ligand-binding domain of the cellular IL-1R (Smith & Chan,
1991) and binds IL-1b with high affinity, preventing IL-1b
from binding its natural receptor (Alcamı´ & Smith, 1992;
Spriggs et al., 1992). A study of the contribution of the B13
and B15 proteins to virus virulence showed that loss of the
B13 protein did not alter virulence in the murine intranasal
model (Kettle et al., 1995) but caused an increase in lesion
sizes after intradermal infection (Tscharke et al., 2002). In
contrast, a virus lacking the B15R gene had reduced
virulence after intracranial infection (Spriggs et al., 1992)
and caused an accelerated weight loss and the induction of
fever after intranasal infection (Alcamı´ & Smith, 1996a). B15
only bound IL-1b, and not IL-1a, TNF or IFNs, and
therefore the ability to block fever was due to inhibition of
IL-1b only. This finding contributed to the conclusion that
IL-1b is the principal endogenous pyrogen (Alcamı´ & Smith,
1996a).
In addition to preventing the production of IL-1b from
infected cells and the capturing of IL-1b in solution, VACV
expresses multiple proteins that can block IL-1-induced
activation of NF-kB. These have been described already
under IFNs. A remarkable feature of the multiple inhibitors
of NF-kB activation is that the removal of A46, A49, A52,
B14, C4 and N1 separately causes an in vivo phenotype
(Bartlett et al., 2002; Harte et al., 2003; Stack et al., 2005;
Chen et al., 2006; Ember et al., 2012; Mansur et al., 2013),
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indicating that these proteins have non-redundant func-
tions. This may be due to a protein having multiple
functions (for instance, N1 can block apoptosis and NF-kB
activation; Maluquer de Motes et al., 2011), multiple
binding partners (e.g. A46; Stack et al., 2005) or being able
to inhibit the pathway at different stages. In the latter case,
cross-talk between signalling pathways can lead to other
signalling pathways being inhibited, or remaining un-
affected, depending upon where inhibition of NF-kB
activation is mediated.
Targeting IL-18
IL-18 (originally termed IFN-c-inducing factor) is also a
member of the IL-1 family and is a pleiotropic, pro-
inflammatory cytokine (Gracie et al., 2003). Like IL-1b, IL-
18 is synthesized as an inactive precursor that requires
cleavage by caspase-1, and the intracellular signalling
pathway induced by binding of IL-18 to the IL-18R has
similarity with IL-1b-induced signalling. IL-18 facilitates
clearance of virus-infected cells by inducing IFN-c synthesis
and activating NK and CD8+ T-cells (Gracie et al., 2003),
and its importance for defence against viruses is illustrated
by IL-18 administration enabling recovery from infection
with VACV or herpes simplex virus type 1 (Fujioka et al.,
1999; Tanaka-Kataoka et al., 1999). VACV has been
predicted, or shown, to inhibit IL-18 action in three ways.
First, the formation of mature IL-18 is predicted to be
inhibited by B13, which inhibits caspase-1. Secondly, VACV
and several other orthopoxviruses secrete a soluble IL-18-
binding protein (IL-18BP), called protein C12, that binds
IL-18 in solution and thereby stops IL-18 reaching the IL-
18R on cells (Born et al., 2000; Smith et al., 2000; Calderara
et al., 2001; Symons et al., 2002a). Unlike protein B15, which
is related to the IL-1R, the VACV IL-18BP is unrelated to the
cellular IL-18R but shows amino acid similarity to the host
IL-18BP, a negative regulator of IL-18 action. Protein C12
enhances VACV virulence by diminishing the production of
IFN-c, leading to reduced NK cell and VACV-specific CD8+
T-cell responses (Reading & Smith, 2003). Thirdly, VACV
inhibits IL-18-induced signal transduction by expressing
intracellular proteins that block NF-kB or IRF activation
(see above).
Targeting TNF
TNF-a and TNF-b, also called lymphotoxin a (LT-a), are
related cytokines that have pro-inflammatory activity and
also can cause cell death. TNF-a is the most studied
member, and has been implicated in tumour regression,
rheumatoid arthritis, septic shock and cachexia (Locksley
et al., 2001). The predominant source of TNF-a is thought
to be macrophages and activated T-cells, and its pleiotropic
activity is attributed to the promotion of an antiviral state
in uninfected neighbouring cells, selective cytolysis of
virus-infected cells, apoptosis and recruitment of lympho-
cytes to foci of infection (Smith et al., 1994). Therefore, it is
unsurprising that viruses have evolved anti-TNF strategies.
These include the secretion of VACV proteins that serve as
decoy TNF receptors (vTNFRs) to sequester extracellular
TNF and preclude cellular receptor binding (reviewed by
Alcamı´, 2003), and also proteins that interfere with
intracellular signalling downstream of host-cell TNFRs
(described above). In addition, TNF is itself an NF-kB
target gene and thus intracellular VACV inhibitors of NF-
kB also affect TNF production.
The majority of VACV strains, including Copenhagen and
WR, encode gene fragments related to vTNFR genes but do
not encode functional TNF-binding proteins (Goebel et al.,
1990; Howard et al., 1991; Smith et al., 1991). However,
VACV strains USSR, Lister and Evans express soluble and
cell-surface vTNFRs encoded by the CrmC (A53R) and
CrmE genes (Alcamı´ et al., 1999). These decoy vTNFRs
exhibit amino acid similarity to the extracellular domains of
cellular TNFRs but lack a membrane anchor and the C-
terminal cytoplasmic domain necessary for signal transduc-
tion (Alcamı´ et al., 1999). The crystal structure of CrmE
confirmed that it has the canonical TNFR fold but showed
that it is closer to the type II TNFR (p75) rather than type I
TNFR (p55) and contains only one of the two ligand-
binding loops of TNFRSF1A, suggesting an explanation for
the higher affinity of poxvirus TNFRs for TNF-a than LT-a
(Graham et al., 2007). Furthermore, VACV CrmE is a
virulence factor, because VACV strain USSR mutants
lacking CrmE were attenuated in a mouse model of
infection, and a recombinant strain of VACV WR expressing
CrmE had increased virulence in the same model (Reading
et al., 2002). Although the expression of vTNFRs is restricted
to a few strains of VACV, CPXV strains express multiple
TNFRs, some of which have additional properties (see
below) (Hu et al., 1994; Smith et al., 1996).
Chemokines
Chemokines are small chemoattractant cytokines that
recruit leukocytes to the site of infection or inflammation
(Rot & von Andrian, 2004; Charo & Ransohoff, 2006).
Chemokines are produced in response to infection or
inflammation and bind to GAGs on the surface of adjacent
endothelial cell walls, where a concentration gradient is
established. Circulating leukocytes express chemokine
receptors on their cell surface that bind to chemokines
via their chemokine receptor-binding site, and thereby
recruit leukocytes to sites of infection (Fig. 5). There are
many different chemokines, which are grouped according
to the position of conserved cysteine residues (C, CC or
CXC, where X is another amino acid), and also many
chemokine receptors. A single chemokine may bind to
several different chemokine receptors and, equally, a single
chemokine receptor may bind several different chemo-
kines. Chemokine production from the first cells infected
by an invading virus is important for induction of the host
response to infection, and without chemokine-mediated
recruitment of leukocytes, the ability of a host to fight
infection is diminished.
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VACV has several ways to inhibit the production or function
of chemokines. After infection, PRR engagement leads to
IRF3 and NF-kB activation and the transcription of many
chemokine genes driven by these transcription factors. For
instance, whilst infection with VACV strain MVA induces
the expression of several chemokines (Lehmann et al., 2009),
infection with VACV strains WR, Wyeth and Lister (Elstree)
does not (Lehmann et al., 2009), owing to their expression of
immunomodulatory proteins that block intracellular sig-
nalling (see above) leading to chemokine production, such
as of CXCL10 (Ferguson et al., 2012).
Secondly, VACV expresses chemokine-binding proteins.
The first to be identified, called VACV chemokine-binding
protein (vCKBP) or VACV CC chemokine inhibitor
(vCCI), binds CC chemokines and is secreted from infected
cells early during infection (Graham et al., 1997; Smith
et al., 1997a; Alcamı´ et al., 1998). vCCI is made by some
but not all VACV strains and binds a range of CC
chemokines with pM affinity, such that it is able to prevent
these chemokines binding to their receptors (Alcamı´ et al.,
1998). The structures of the orthologue of vCCI from
CPXV (Carfi et al., 1999) and from VACV strain rabbitpox
in complex with CCL4 (macrophage inflammatory protein
1b) have been solved (Zhang et al., 2006). The latter study
provided insight into how vCCI binds CC chemokines with
high affinity and broad specificity. A second protein, A41,
shows amino acid similarity to vCCI and is also secreted
from infected cells early during infection (Ng et al., 2001).
A41 binds chemokines (CCL21, CCL25, CCL26 and
CCL28) with lower affinity (between 8 and 118 nM) and
is unable to prevent chemokines binding to chemokine
Fig. 5. Mechanisms of chemokine inhibition by VACV. Chemokines are released from sites of infection and establish
concentration gradients on the endothelial cell wall by binding to GAGs. The chemokines then bind to and activate circulating
leukocytes, which are recruited to the site of infection. VACV protein vCCI prevents binding of CC chemokines to chemokine
receptors on leukocytes (top), whereas protein A41 prevents the establishment of the chemokine concentration gradient
(bottom). See text for details.
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receptors due to this low affinity (Bahar et al., 2008). A41
has a similar structure to vCCI, but there are surface charge
differences and an extended acidic loop that may
contribute to chemokine-binding specificity (Bahar et al.,
2008). A41 binding to chemokines was inhibited by
heparin, indicating that the heparin and chemokine-
binding sites overlap and suggesting that the mechanism
of action of A41 is via the disruption of chemokine
concentration gradients on endothelial cells (Bahar et al.,
2008) (Fig. 5). A parallel study with the closely related
ECTV protein E163 came to broadly similar conclusions
(Ruiz-Arguello et al., 2008).
The role of A41 and vCCI in vivo is to diminish
inflammation by preventing recruitment of leukocytes to
the site of infection. Thus, when vCCI is expressed from
VACV strain WR, which lacks this protein normally (Alcamı´
et al., 1998), the recombinant virus is less virulent in a
murine intranasal model in which pathology is associated
with excessive inflammation (Reading et al., 2003b). For
A41, a VACV WR strain lacking this gene produced larger
lesion sizes than controls in a murine intradermal model,
but the infectious virus was cleared more rapidly due to
greater recruitment of leukocytes (Ng et al., 2001).
VACV strain WR proteins B7 and B23 were predicted to
have chemokine-binding activity because they share
sequence similarity with protein E184 from ECTV, protein
V216 from CPXV and the C-terminal domain from TNFRs
CrmB and CrmD from CPXV and variola virus, which have
been demonstrated to bind chemokines (Alejo et al., 2006).
Interestingly, the structure of the chemokine-binding
domain of CrmD from ECTV in complex with CX3CL1
showed that this domain shares structural similarity with the
vCCI and A41 proteins (Xue et al., 2011).
Apoptosis
Apoptosis is an irreversible cascade of biochemical events
orchestrated by caspase proteases that culminates in cell
death and represents a powerful mechanism to eliminate
virus-infected cells (Tait & Green, 2010). Activation of
apoptosis by the intrinsic pathway is controlled by a
complex network of protein–protein interactions between
pro-apoptotic and anti-apoptotic members of the Bcl-2
family of proteins. In response to apoptotic signals, pro-
apoptotic proteins such as Bad or Bid bind the effector
proteins Bax and Bak, which oligomerize in the outer
mitochondrial membrane inducing release of cytochrome c
into the cytoplasm and formation of the caspase activation
platform or apoptosome (Fig. 6). VACV directly subverts
the intrinsic pathway by expressing proteins F1 and N1.
Protein F1 adopts a Bcl-2-like fold (Kvansakul et al., 2008)
and binds Bak at the mitochondrion (Wasilenko et al.,
2003, 2005; Postigo et al., 2006; Kvansakul et al., 2008). F1
also reduces the inflammatory response by binding NLRP-1,
an upstream activator of caspase-1 (Gerlic et al., 2013).
Protein N1 also has a Bcl-2 fold (Aoyagi et al., 2007; Cooray
et al., 2007) and contains a surface groove that enables it to
bind pro-apoptotic Bcl-2 proteins Bid and Bad and to
inhibit apoptosis (Cooray et al., 2007; Maluquer de Motes
et al., 2011). N1 was also reported to bind peptides
containing Bcl-2 homology domain 3 (BH3) domains of
pro-apoptotic Bcl-2 proteins Bid, Bim and Bak in vitro
(Aoyagi et al., 2007). Other studies found no interaction
between N1 and Bax or N1-mediated inhibition of apoptosis
(Banadyga et al., 2009; Postigo & Way, 2012). Nonetheless,
mutagenesis of N1 showed that loss of binding to Bid and
Bad correlated with loss of anti-apoptotic activity whilst
retaining anti-NF-kB activity (Maluquer de Motes et al.,
2011). Interestingly, for both F1 and N1, inhibition of innate
immune signalling was more important for virus virulence
than inhibition of apoptosis (Maluquer de Motes et al.,
2011; Gerlic et al., 2013).
In addition to these viral Bcl-2-like proteins, VACV strain
WR B13 (SPI-2) (Smith et al., 1989; Kettle et al., 1995)
inhibits caspase-1 activity as well as extrinsic apoptosis
triggered by TNF-a or Fas ligand (Dobbelstein & Shenk,
1996; Kettle et al., 1997). The CPXV orthologue of B13
(CrmA) inhibits caspases from group I (caspase-1, -4 and
-5) and group III (caspase-8, -9 and -10) (Ray et al., 1992;
Zhou et al., 1997; Garcı´a-Calvo et al., 1998), and similar
specificity is expected for VACV protein B13 due to
conservation of the reactive site. This may explain how
B13 inhibits both extrinsic apoptosis and the host
inflammatory response. Furthermore, VACV inhibitors such
as the dsRNA-binding protein E3 can show protective effects
on cells when neutralizing pro-apoptotic effects of external
stimuli like dsRNA (Kibler et al., 1997; Garcı´a et al., 2002).
Lastly, a few VACV strains, such as Evans, and also camelpox
virus (Gubser & Smith, 2002) express a protein called viral
Golgi anti-apoptotic protein (vGAAP) that is closely related
(73 % amino acid identity) to a human orthologue, hGAAP
(Gubser et al., 2007). GAAPs are highly conserved
throughout evolution, being present in all eukaryote
genomes examined, and are part of the transmembrane
Bax inhibitor-containing motif (TMBIM) family, which
includes other anti-apoptotic and Ca2+-modulating mem-
brane proteins such as Bax inhibitor I. vGAAP and hGAAP
have a six-membrane topology (Carrara et al., 2012), form
oligomers (Saraiva et al., 2013a) and modulate calcium in
intracellular stores (de Mattia et al., 2009). hGAAP also
promotes cell adhesion and migration via the stimulation of
store-operated Ca2+ entry and calpain 2 (Saraiva et al.,
2013b). hGAAP and vGAAP can protect cells from apoptosis
deriving from both intrinsic and extrinsic pathways (Gubser
et al., 2007). vGAAP and B13 are only expressed by the
minority of VACV strains, whereas proteins F1 and N1 are
more widely conserved. Nonetheless, deletion of any of these
proteins gives an in vivo phenotype (Bartlett et al., 2002;
Tscharke et al., 2002; Gubser et al., 2007; Gerlic et al., 2013).
NK cells
NK cells are a specialized population of granular lympho-
cytes displaying high cytolytic activity against virus-infected
and tumour cells. They serve as a first line of defence against
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viral infections before the development of a virus-specific
antibody and CTL response. NK cell activation depends on
cytokines such as IFN-a, IFN-b, IL-12 and IL-18 but is
mostly regulated by a repertoire of activating and inhibitory
receptors that integrate signals emanating from the surface
of target cells (Lanier, 2005). Most NK inhibitory receptors
recognize MHC class I molecules, and this ensures tolerance
against self-antigens. In contrast, CD16, NKG2D and the
natural cytotoxicity receptors NKp46, NKp44 and NKp30
are mostly involved in the activation of NK cells (Lanier,
2005).
It is well known that NK cells play an important role
against poxvirus infections: for instance, the resistance of
B6 mice to ECTV maps to genes involved in activation and
regulation of NK cell responses (Delano & Brownstein,
1995), and depletion of NK cells with anti-asialo GM1 or
anti-NK1.1 antibodies increases susceptibility to VACV
(Bukowski et al., 1983; Martinez et al., 2010). In addition,
VACV infection induces proliferation and accumulation of
NK cells at the site of infection (Natuk & Welsh, 1987;
Dokun et al., 2001; Jacobs et al., 2006), and VACV can
modulate NK cell activation by modulating production of
Fig. 6. Pathways of apoptosis and their inhibition by VACV. Apoptosis can be induced by signals from either outside (extrinsic)
or inside (intrinsic) the cell. The release of cytochrome c and activation of the apoptotic protease activator factor 1 (APAF1) from
the mitochondrion to form the apoptosome is central in the induction of apoptosis. The apoptosome then activates a series of
initiator and executioner caspases that lead to apoptosis. External stimuli like the Fas ligand or TNF can activate caspases
directly. In non-apoptotic cells, the engagement of Fas receptor (FasR) or TNF receptor (TNFR), or intrinsic signals resulting
from the withdrawal of growth factors, lead to activation of the pro-apoptotic proteins Bid and Bad. These then sequester anti-
apoptotic proteins Bcl-2 and Bcl-xL enabling formation of Bax/Bak-mediated mitochondrial pores. This causes cytochrome c
release from the mitochondrion. VACV protein N1 targets Bid and Bad upstream in the signalling cascade, whereas VACV
protein F1 neutralizes Bak in the mitochondrial membrane. VACV protein B13 inhibits caspase-1 and the apoptotic processes
where it is involved. vGAAP is an integral membrane protein present in the Golgi and causes a reduction in Ca2+ loading of
intracellular stores, so that less Ca2+ can be released by pro-apoptotic pathways.
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cytokines and IFN (see above). VACV infection increases
cell susceptibility to NK lysis (Brutkiewicz et al., 1992; Baraz
et al., 1999; Chisholm & Reyburn, 2006), and in specific
cases this has been attributed to selective downregulation of
HLA-E or C-type lectin related protein b (Clr-b) (Brooks
et al., 2006; Williams et al., 2012). Protection against VACV
challenge can also be mediated by passive transfer of NK cells
from VACV-infected mice lacking classical adaptive T- and
B-lymphocytes (Gillard et al., 2011).
Susceptibility to NK cells occurs after virus-mediated
downregulation of MHC class I, a process employed by
viruses to escape recognition by CTLs. Whereas VACV is
known to modestly decrease MHC class I expression
(Brutkiewicz et al., 1992; Kirwan et al., 2006), it seems that
only downregulation of HLA-E is sufficient to induce lysis
by NK cells (Brooks et al., 2006). Studies in vitro have
shown that NK cell recognition of VACV-infected cells
depends on the natural cytotoxicity receptor (Chisholm &
Reyburn, 2006). Recently, the VACV haemagglutinin
(protein A56) was identified as a novel viral ligand for
the activating receptors NKp30 and NKp46 (Jarahian et al.,
2011). Upon binding to A56, NKp46 triggered NK
cytotoxicity, but NKp30 activity was neutralized, which
exemplifies the delicate interplay between VACV and its
host. The same study revealed minimal alteration of
NKG2D ligands after VACV infection of human cells.
This is in contrast to other studies demonstrating a key role
for NKG2D in the control of VACV (Martinez et al., 2010)
or ECTV (Fang et al., 2008, 2011) infection in vivo. This
indicates that different NK receptors are responsible for the
control of genetically similar poxvirus species and strains in
different hosts. To date, A56 is the only described VACV
direct modulator of NK cell activity, although removal of
several VACV proteins, including N1, F3, C12 and K7,
altered the NK response to infection and this is probably
due to their ability to block intracellular signalling cascades
leading to production of cytokines or chemokines (Reading
& Smith, 2003; Froggatt et al., 2007; Jacobs et al., 2008;
Benfield et al., 2013). Other VACV mechanisms to evade
NK recognition may exist.
The influence of VACV immunomodulators on
virulence and immunogenicity
Virulence
Many of the VACV immunomodulatory genes described
above are non-essential for virus replication in cell culture
but affect virulence in vivo, where the innate immune
response plays an important role in determining the
outcome of infection. Two murine models of infection are
used routinely to study VACV virulence: the intradermal
model where inoculation of the ear pinnae causes a localized
infection resulting in the formation of a lesion (Tscharke &
Smith, 1999), and the intranasal infection route, which
results in a systemic infection causing mice to lose weight
(Williamson et al., 1990). In addition, virulence has also
been investigated using intracranial and intraperitoneal
injection, dermal scarification to the base of the tail, or by
using rabbits and guinea pigs. The removal or inactivation of
most immunomodulatory genes leads to reduced virus
virulence in either the intranasal or intradermal infection
model (Table 1). In many instances, attenuation is
accompanied by increased immune cell infiltrates to the
site of infection and/or decreased viral titres after the initial
virus replication (see Table 1 for references). In some cases
deletion of immunomodulatory genes leads to attenuation
in more than one model of infection (Tscharke et al., 2002).
Further work is required to understand why these
differences exist. In certain instances, the removal of an
immunomodulatory gene can lead to an increase in
virulence; for example, VACV strain WR viruses engineered
to lack the A41 (Ng et al., 2001; Clark et al., 2006) or B15
(Alcamı´ & Smith, 1992; 1996a) proteins, or to express vCCI/
vCKBP (Reading et al., 2003b), produce immune pathology.
Immunogenicity
The adaptive immune system includes antibody (‘humor-
al’) and cell-mediated responses that are mediated by
antibody-secreting B-lymphocytes and cytotoxic (CD8+)
and Th1 (CD4+) T-lymphocytes, respectively. Adaptive
immunity is characterized by its delayed onset, targeting of
pathogen-specific antigens and immunological memory,
and is the basis for vaccination. Both humoral and CD4+
and CD8+ T-cell responses are induced by VACV infection
in mice (Xu et al., 2004) and humans (Ennis et al., 2002;
Crotty et al., 2003; Hammarlund et al., 2003; Kennedy et al.,
2004; Pu¨tz et al., 2005, 2006; Moutaftsi et al., 2010). Efforts
to dissect the relative roles of these responses in the mouse
model using antibody depletion and gene knock-
out showed that the CD4+ T-cell-dependent antibody
response is more important for viral clearance, whilst
CD8+ T-cells limit disease severity and mediate protective
memory upon reinfection (Xu et al., 2004). T-cell
responses are evidently important for the response to
infection with VACV because individuals with defects in
cellular immunity are at risk of serious complications from
vaccination (Lane et al., 1969). For a review of the response
to smallpox vaccination, see Moss (2011).
VACV is being studied intensely as a vaccine vector and, in
particular, the highly attenuated VACV strains MVA and
NYVAC (Tartaglia et al., 1992) are being tested as vaccines
for several diseases including AIDS, malaria, tuberculosis
and some cancers (Gomez et al., 2008; Walsh & Dolin,
2011). MVA is a promising vaccine vector due to its safety
record, efficient expression of foreign antigens and ability
to induce a robust immune response (Sutter & Moss,
1992). MVA does not replicate fully in most mammalian
cell lines (Sutter & Moss, 1992; Blanchard et al., 1998;
Okeke et al., 2006) and is a safe vaccine even in immune-
compromised mammals (Wyatt et al., 2004).
MVA was generated by the passage of chorioallantois
VACV Ankara more than 500 times in chicken embryo
fibroblasts, resulting in the loss of large portions of the
G. L. Smith and others
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genome and substantial attenuation of the virus (Meyer
et al., 1991; Antoine et al., 1998). Despite these deletions, a
significant number of immunomodulatory genes remain in
the MVA genome (Antoine et al., 1998; Blanchard et al.,
1998). However, retention of an ORF does not ensure that
the function of the encoded protein is retained, as
illustrated with protein 183 (equivalent to VACV WR
protein B14), which is rendered unstable by an internal
deletion of 5 aa (McCoy et al., 2010). Removal of the
chemokine-binding protein encoded by A41L (Clark et al.,
2006) or the IL-1b-binding protein encoded by B15R (WR)
(Staib et al., 2005) led to enhanced VACV-specific total
CD8+ T-cell responses and enhanced protection against
a challenge with virulent VACV WR. The deletion of
A35R, encoding an inhibitor of MHC class II antigen
presentation, from MVA also resulted in enhanced
immunogenicity, with increased numbers of VACV-
specific IFN-c-secreting splenocytes, enhanced immuno-
globulin production and class switching to IgG isotypes
(Rehm & Roper, 2011). Deletion of the IL-18-binding
protein, C12L (also from MVA), led to increased CD8+
and CD4+ T-cell responses to various VACV epitopes and
provided enhanced protection against WR challenge
(Falivene et al., 2012). Furthermore, a deletion mutant of
C6L from the WR strain of VACV led to enhanced VACV-
specific cytotoxicity of T-cells and provided better
protection against challenge with a lethal dose of WR
(Sumner et al., 2013).
Recently, several VACV vectors have been generated for
immunization trials against HIV infection and their
immunogenicity has been investigated. These include
MVA-B, a vector expressing four HIV antigens and
engineered to lack either both A41L and B15R (Garcı´a-
Arriaza et al., 2010) or the IRF3 inhibitor C6L (Garcı´a-
Arriaza et al., 2011). These viruses induced HIV-1-specific
CD4+ and CD8+ T-cell immune responses of enhanced
magnitude and polyfunctionality. For the C6L deletion
mutant, enhanced levels of antibodies against the HIV Env
protein were also observed. Furthermore, individual and
double deletion mutants of the type I (B18) and type II
(B8) IFN-binding proteins from NYVAC-C (which
expresses the HIV-1 Env, Gag, Pol, and Nef antigens)
improved HIV-1-specific CD8+ T-cell responses (Gomez
et al., 2012). Finally, an MVA vector expressing codon-
optimized HIV subtype C Env and Gag antigens and
lacking four or five viral immunomodulators, including
C12, B15, a dominant negative Toll/IL-1 signalling
adaptor, a CC chemokine-binding protein and a gene
encoding uracil-DNA glycosylase, elicited higher frequen-
cies of HIV-specific CD8+ and CD4+ T-cells and higher
titres of Env-specific antibodies in immunized rhesus
macaques (Garber et al., 2012). Whether these VACV-
based HIV vaccine vectors provide enhanced protection
against infection remains to be determined.
Despite promising data with the recombinant VACVs
described above, deletion of immunomodulatory genes
does not always enhance immunogenicity. For instance, a
VACV WR lacking C16L (Fahy et al., 2008) or N2L
(Ferguson et al., 2013) and a VACV Wyeth lacking regions
encoding the B5R, B8R, B12R, B13R, B14R, B16R, B18R
and B19R genes, a number of which are immunomodu-
lators (Jackson et al., 2005), showed unaltered immuno-
genicity under the conditions tested. It is likely that
immunogenicity will reflect a balance between efficient
recognition of virus antigens and the level of antigens
expressed during infection (Wyatt et al., 2008). Under-
standing why the removal of certain immunomodulators
enhances immunogenicity, whilst that of others does not,
remains a goal of future research and will aid in the
rational design of more efficacious vaccine vectors.
Future prospects
Therapeutics
As well as having applications for the development of
vaccines, progress towards understanding how VACV
evades and disrupts the immune system has important
implications for the design and production of novel
therapeutics. These can be split into three categories: (i)
using modified forms of the virus; (ii) using recombinant
viral proteins; and (iii) designing compounds that mimic
the specific activity of viral proteins. The first two
categories have examples that are now in clinical trials,
whilst the third category is at a less advanced stage.
Other than as a vaccine, the therapeutic use of VACV as an
oncolytic agent shows promise. Oncolytic viruses are those
that can selectively, or preferentially, replicate in and kill
tumour cells (Thorne, 2011). VACV has several advantages
for this type of therapy, such as its broad tissue tropism, its
ability to spread rapidly, the considerable experience with
its use clinically during the eradication of smallpox, and the
fact that it does not integrate its DNA into the host genome
(Kirn & Thorne, 2009). Use of unmodified strains of
VACV, such as WR and Lister, has proved less effective
than other species of oncolytic viruses due to their lack of
tumour specificity (Kirn & Thorne, 2009). However, a
greater understanding of VACV immunogenicity and
immune evasion mechanisms is enabling the design of
modified viruses that have greater efficacy against cancer
(Kirn & Thorne, 2009; Schmidt, 2011; Thorne, 2011). For
example, the JX-594 virus, which is a thymidine kinase-
negative VACV engineered to express granulocyte–macro-
phage colony stimulating fctor (GM-CSF), specifically lyses
neoplastic cells and has undergone phase II clinical trials
for the treatment of solid tumours such as advanced
hepatocellular carcinoma (Breitbach et al., 2011; Heo et al.,
2013). Furthermore, the removal of certain VACV immune
evasion genes, such as B18, which inhibits type I IFN,
improved its oncolytic potential, suggesting that immune
modulation plays an important part in the activity of these
viruses when attacking tumours (Kirn et al., 2007; Thorne,
2011). It is probable, therefore, that this promising
approach will be improved by further modifications of
VACV. For example, deletion of additional immune
Vaccinia virus immune evasion
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Table 1. VACV immune modulators affecting virulence
Strain Protein Function Intranasal Intradermal Intracranial References
WR A35 Inhibitor of MHC class II
antigen presentation
Attenuated Roper (2006)
Cop (WR) A39 Secreted glycoprotein, aa
similar to semaphorins
Attenuated Smaller lesion Gardner et al. (2001)
WR A40 Surface glycoprotein. Immune
modulator
No phenotype Smaller lesion Wilcock et al. (1999); Tscharke
et al. (2002)
WR A41 Secreted chemokine-binding protein Increased virulence Larger lesion, more
rapid virus clearance
Ng et al. (2001); Clark et al.
(2006)
WR A44 3b-Hydroxysteroid dehydrogenase Attenuated Smaller lesion Moore & Smith (1992); Tscharke
et al. (2002); Reading et al.
(2003a)
WR A46 NF-kB/IRF3 inhibitor Attenuated Stack et al. (2005)
WR A49 NF-kB inhibitor Attenuated No phenotype Mansur et al. (2013)
WR A52 NF-kB inhibitor Attenuated Harte et al. (2003)
WR A53 Soluble TNF receptor (CrmC) Attenuated No phenotype (rabbit) Attenuated Dai et al. (2008)
WR A55 Intracellular kelch protein
immunomodulator
No phenotype Larger lesion Beard et al. (2006)
WR A56 NK cell agonist/antagonist No phenotype Attenuated Flexner et al. (1987); Smith et al.
(2002)
WR B7 ER protein, putative chemokine-
binding protein
No phenotype Smaller lesion Price et al. (2000)
WR B8 Secreted IFNc binding protein No phenotype/attenuated Histological changes in
rabbit skin
Verardi et al. (2001); Symons
et al. (2002b)
WR B13 Inhibitor of caspases No phenotype/attenuated Larger lesion Kettle et al. (1995); Tscharke
et al. (2002); Legrand et al.
(2004)
WR B14 NF-kB inhibitor No phenotype Smaller lesion, more
rapid virus clearance
Chen et al. (2006)
WR B15 Secreted IL-1b binding protein Increased virulence (high virus dose)/
attenuated (low virus dose)
No phenotype Attenuated Alcamı´ & Smith (1992, 1996a);
Spriggs et al. (1992); Tscharke
et al. (2002)
WR B18 Type I IFN binding protein Attenuated Symons et al. (1995)
WR B22 Serine protease inhibitor No phenotype/attenuated Kettle et al. (1995); Legrand et al.
(2004)
WR C2 Intracellular kelch protein
immunomodulator
No phenotype Larger lesion Pires de Miranda et al. (2003)
WR C4 NF-kB inhibitor Attenuated No phenotype Ember et al. (2012)
WR C6 IRF3 inhibitor Attenuated Smaller lesion Unterholzner et al. (2011);
Sumner et al. (2013)
WR & Tian
Tan
C12 IL-18-binding protein Attenuated Smaller lesion (rabbits) Attenuated Symons et al. (2002a); Reading &
Smith (2003); Dai et al. (2008)
WR C16 Binds DNA-PK Attenuated No phenotype Fahy et al. (2008)
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evasion genes may help the destruction of specific tumours
and optimize the adaptive immune response to provide
long-term remission (Wang et al., 2012).
As described above, VACV secretes proteins from infected
cells that bind to cytokines, chemokines and IFNs, such as
B18, which binds type I IFNs (Colamonici et al., 1995;
Symons et al., 1995). The secreted nature of such proteins
makes them attractive therapeutics because they are stable
outside the cell and are easy to express and purify. Such
proteins may be used to treat both acute and chronic
inflammatory conditions such as rheumatoid arthritis,
where hyperactive or dysregulated inflammatory processes
results in tissue destruction (Fallon & Alcamı´, 2006),
although as foreign proteins their repeated administration
will eventually induce an antibody response that will
restrict their activity. As an example, vCCI binds a wide
range of CC chemokines (Alcamı´ et al., 1998; Burns et al.,
2002) and, in an in vivo inflammatory model, can mediate
effective reductions of eotaxin-induced eosinophilia
(Alcamı´ et al., 1998). The potential of these proteins as
therapeutics is best illustrated by SERP-1, a poxvirus serine
protease inhibitor (Upton et al., 1990), which reduces
vascular inflammation in patients with acute coronary
syndromes and has undergone phase II clinical trials in
patients receiving cardiac stents (Tardif et al., 2010).
VACV intracellular immunomodulators are harder to
deliver as therapeutic agents. The functions of several of
these proteins, however, represent attractive therapeutic
targets. For example, inhibitors of IKKb are sought as
therapy for treatment of inflammatory diseases such as
rheumatoid arthritis and chronic obstructive pulmonary
disease, as well as cancer, thanks to their potential to block
NF-kB activation (Luo et al., 2005; Lee & Hung, 2008).
Indeed, several IKKb kinase inhibitors are in clinical trials
(Lee & Hung, 2008). As VACV WR protein B14 binds to
and inhibits the activity of IKKb (Chen et al., 2008), its
function might be mimicked by a small molecule to
provide a novel therapeutic. This approach relies on a more
detailed structural understanding of the interaction
between IKKb and B14, but as B14 is not a kinase inhibitor
and instead blocks the phosphorylation of IKKb itself
(Chen et al., 2008), this information may reveal a novel
allosteric target site for IKKb inhibition. In a similar vein,
the function of C6 could be mimicked to provide a novel
TBK1 inhibitor (Unterholzner et al., 2011). TBK1 is
considered a therapeutic target for rheumatoid arthritis
(Hammaker et al., 2012) and certain specific cancers
(Migita & Nakamura, 2012). Proof of principle for this
approach has been provided by the development of peptide
mimetics of the VACV A52 (McCoy et al., 2005) and A46
(Lysakova-Devine et al., 2010) proteins. These peptides
have a cell-penetrating peptide at the N terminus to allow
cell entry and inhibit TLR signalling, thereby blocking
inflammatory responses both in vitro and in vivo (McCoy
et al., 2005; Lysakova-Devine et al., 2010). TLR inhibitors
are sought as targets for many inflammatory disorders
(Kanzler et al., 2007) and compounds such as theseT
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peptides can provide the specificity needed to inhibit specific
aspects of TLR signalling necessary for such treatments.
Vaccines
Following the development of VACV as an expression
vector in 1982, its potential as a vaccine vector has been
investigated extensively. Although attenuated VACV
strains have a good safety profile, improving immuno-
genicity remains a priority (Jacobs et al., 2009), and this
depends on a deeper understanding of the effects of VACV
immunomodulators on the immune response. Deletion of
immunomodulators is one strategy to increase VACV
immunogenicity. As outlined above, VACV encodes many
immunomodulator genes, and in several cases their
deletion has increased the immune response to VACV
and provided better protection against challenge.
An alternative attenuation strategy is to express host genes
encoding immunomodulatory proteins in VACV. For
example, expression of IL-2 (Flexner et al., 1987), IFN-c
(Kohonen-Corish et al., 1990), IFN-ls (Bartlett et al., 2005)
and IL-15 (Perera et al., 2007) in VACV WR caused a
reduction in virus virulence, and in the latter case there was
also a greater CD8+ T-cell memory response and an
enhanced cellular and humoral response (Perera et al.,
2007). However, this strategy requires care because of the
potential of some cytokines to increase virus virulence, as
illustrated by the expression of IL-4 in VACV (Sharma
et al., 1996) and ECTV (Jackson et al., 2001). A further
possibility is the expression of immune-stimulating
proteins that can selectively enhance recruitment and
activation of specifically targeted immune cells, such as
antigen-presenting cells, and thereby induce a more
selective and specific immune response. For instance,
increased anti-MVA antibody titre and an increased
cellular immune response were obtained with an MVA
strain expressing GM-CSF or CCL20 in mice (Chavan et al.,
2006).
In spite of the large number of studies and applications of
VACV, a clear understanding of the immunological basis of
its protective properties is lacking (Moss, 2011). The
immunogenicity of VACV is striking considering the large
number of immunosuppressive proteins expressed by the
virus. Recent studies have started unravelling the fun-
damental mechanisms by which the innate immune system
orchestrates the adaptive response and protective response
to vaccination (Pulendran & Ahmed, 2006). The study of
VACV immune evasion may help identify specific
molecular signatures in the early response to vaccination
that correlate with the development of a protective
immune response, or indicate how different subsets of T-
cells or antibodies influence protection. Such studies may
also illustrate how their induction can be fine tuned, and
how different components of the innate immune system
interact to integrate signals that impact on adaptive
immunity. Recent advances in virus immunology and the
application of vaccine engineering, proteomics and systems
biology to the study of vaccines can help address these
issues and provide information on how the immune system
responds to vaccination (Querec et al., 2009; Pulendran
et al., 2010). A deeper understanding of VACV and its
multitude of immunomodulators has the potential to
reveal the underlying signalling networks that underpin
development of immunological protection, and to enable
more rational vaccine design.
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